# Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

> **NCT00258232** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** celecoxib
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00258232
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2007-03
- **Final completion:** 2007-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258232, "Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00258232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*